Is Alkermes plc. (ALKS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.5% / 30% | 12.3% / 30% | 7.0% / 30% | 3.07% / 5% | ✓ HALAL |
| DJIM | 1.5% / 33% | 12.3% / 33% | 7.0% / 33% | 3.07% / 5% | ✓ HALAL |
| MSCI | 2.8% / 33% | 23.7% / 33% | 13.4% / 33% | 3.07% / 5% | ✓ HALAL |
| S&P | 1.5% / 33% | 12.3% / 33% | 7.0% / 33% | 3.07% / 5% | ✓ HALAL |
| FTSE | 2.8% / 33% | 23.7% / 33% | 13.4% / 50% | 3.07% / 5% | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 86.7% | |
| Operating Margin | 15.1% | |
| Net Margin | 16.4% | |
| Return on Equity (ROE) | 14.7% | |
| Return on Assets (ROA) | 7.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $521M |
| Free Cash Flow | $480M |
| Total Debt | $70M |
| Debt-to-Equity | 3.8 |
| Current Ratio | 3.5 |
| Total Assets | $2.5B |
Price & Trading
| Last Close | $29.92 |
| 50-Day MA | $31.28 |
| 200-Day MA | $29.66 |
| Avg Volume | 2.0M |
| Beta | 0.5 |
|
52-Week Range
$25.17
| |
About Alkermes plc. (ALKS)
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Purification Calculator
As a halal stock with 3.07% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Alkermes plc. (ALKS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Alkermes plc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Alkermes plc.'s debt ratio?
Alkermes plc.'s debt ratio is 1.5% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.8%.
Does Alkermes plc. require dividend purification?
Yes, Alkermes plc. has an impermissible income ratio of 3.07%, which means 3.07% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are Alkermes plc.'s key financial metrics?
Alkermes plc. has a market capitalization of $4.9B, trailing P/E ratio of 20.6, and revenue of $1.5B. The company maintains a gross margin of 86.7% and a net margin of 16.4%. Return on equity stands at 14.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.